Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 483 full-time employees. The company went IPO on 2020-02-06. The firm's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Follow-Up Questions
Beam Therapeutics Inc의 CEO는 누구입니까?
Mr. John Evans은 2017부터 회사에 합류한 Beam Therapeutics Inc의 Chief Executive Officer입니다.
BEAM 주식의 가격 성능은 어떻습니까?
BEAM의 현재 가격은 $26.41이며, 전 거래일에 increased 1.67% 하였습니다.
Beam Therapeutics Inc의 주요 사업 주제나 업종은 무엇입니까?
Beam Therapeutics Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Beam Therapeutics Inc의 시가총액은 얼마입니까?
Beam Therapeutics Inc의 현재 시가총액은 $2.6B입니다
Beam Therapeutics Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 15명의 분석가가 Beam Therapeutics Inc에 대한 분석 평가를 실시했으며, 이는 9명의 강력한 매수, 10명의 매수, 3명의 보유, 0명의 매도, 그리고 9명의 강력한 매도를 포함합니다
